Status:
TERMINATED
Evaluation of FDY-5301 in Major Trauma Patients in ICU
Lead Sponsor:
Faraday Pharmaceuticals, Inc.
Conditions:
ICU Acquired Weakness
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of FDY-5301 compared to placebo in major trauma ICU patients at risk of intensive care unit acquired weakness (...
Detailed Description
The purpose of the trial is to evaluate the efficacy, safety, and PK of FDY-5301 compared to placebo in trauma ICU patients at risk of ICUAW. Muscle wasting occurs rapidly after major trauma and is o...
Eligibility Criteria
Inclusion
- Age 18-75 years
- Major trauma defined as:
- thoracic and/or abdominal and/or pelvic injury
- necessitating admission to ICU with ventilation anticipated for at least 24 hrs
- hemorrhagic shock defined as systolic blood pressure (SBP) \<90 mmHG requiring blood transfusion or base deficit of at least 6mEq/L pre-hospital arrival or within one hour after hospital arrival
- IRB/IEC-approved consent obtained within 48 hours of first hospital arrival time (i.e., in case of transfers, use time of arrival to first hospital immediately post injury)
Exclusion
- Likely to die within 48 hrs from time of screening
- Any neurological condition that is perceived at the time of hospital admission as an immediate threat to life or incompatible with good functional recovery and where early limitation or withdrawal of therapy is being considered. For example:
- a. Computed tomography imaging showing evidence of traumatic brain injury (TBI), combined with best representative Glasgow Coma Score (GCS) Motor Score of ≤4 at approximately 24 hrs post injury
- Evidence of nonreversible spinal cord injury
- Bilateral femoral fractures
- Women who are pregnant or breastfeeding. Women of reproductive potential must have a negative serum pregnancy test prior to randomization.
- Known thyroid disease or thyroid disorder, including subjects on thyroid hormone replacement therapy at the time of randomization
- Known allergy to iodine
- Chronic renal disease requiring dialysis
- Body mass index (BMI) \>40 kg/m2 or \<16 kg/m2
- Body weight (BW) \>140 kg (or \>309 lb)
- History or presence of debilitating neurologic or other neuromuscular disease (e.g., spina bifida, amyotrophic lateral sclerosis, multiple sclerosis) at time of randomization
- Current metastatic cancer
- Solid organ transplant recipient
- Evidence of pre-existing sarcopenia defined as having a pre-trauma Clinical Frailty Score (CFS) of ≥5 or based on clinical judgement (e.g. frail by appearance, cachexia, etc.)
- Use of systemic corticosteroids, immunomodulators, or oncologic chemotherapy within 6 months of randomization (inhaled and topical steroids are allowed)
- Use of investigational drugs or devices within 30 days of randomization
- Any clinically significant abnormality identified prior to randomization that in the judgment of the Investigator or Sponsor would preclude safe completion of the study, or confound the anticipated benefit of FDY-5301
Key Trial Info
Start Date :
September 20 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 4 2022
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT04430283
Start Date
September 20 2021
End Date
March 4 2022
Last Update
June 13 2023
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Harbor-UCLA Medical Center
Torrance, California, United States, 90509
2
University of Florida Health Shands Hospital
Gainesville, Florida, United States, 32610
3
Massachusetts General Hospital, Harvard Medical School
Boston, Massachusetts, United States, 02114
4
The Ohio State University Wexner Medical Center
Columbus, Ohio, United States, 43210